Breaking News Instant updates and real-time market news.

NVS

Novartis

$89.12

-0.2 (-0.22%)

, BMY

Bristol-Myers

$44.45

0.25 (0.57%)

09:22
07/17/19
07/17
09:22
07/17/19
09:22

Investors shouldn't overreact to drug proposal headlines, says Raymond James

Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

NVS

Novartis

$89.12

-0.2 (-0.22%)

BMY

Bristol-Myers

$44.45

0.25 (0.57%)

JNJ

Johnson & Johnson

$132.46

-2.21 (-1.64%)

AZN

AstraZeneca

$40.20

-0.005 (-0.01%)

GSK

GlaxoSmithKline

$41.19

0.29 (0.71%)

RHHBY

Roche

$0.00

(0.00%)

MRK

Merck

$81.57

0.62 (0.77%)

LLY

Eli Lilly

$108.81

0.36 (0.33%)

SNY

Sanofi

$41.82

0.18 (0.43%)

PFE

Pfizer

$42.85

0.1 (0.23%)

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

NVS Novartis
$89.12

-0.2 (-0.22%)

06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
BMY Bristol-Myers
$44.45

0.25 (0.57%)

06/25/19
WBLR
06/25/19
NO CHANGE
WBLR
Outperform
Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair
William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.
06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.
JNJ Johnson & Johnson
$132.46

-2.21 (-1.64%)

07/12/19
WELS
07/12/19
NO CHANGE
Target $29
WELS
Outperform
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
Wells Fargo analyst David Maris believes Australia's proposal to ban, suspend or impose strict restrictions on a number of textured implants from Allergan (AGN), Johnson & Johnson (JNJ) and other smaller manufacturers is "excellent news" for Establishment Labs Holdings (ESTA). The move by Australia's regulatory body Therapeutic Goods Administration will help solidify Establishment's reputation for safety as the company's Motiva brand is the only listed company without any restricted brands, Maris tells investors in a research note. Further, Australia is a highly regulated and developed market, so the ban could help shift market share in other geographies outside of the county as well, contends the analyst. Maris reiterates an Outperform rating on Establishment Labs with a $29 priced target. The stock closed yesterday up $1.54 to $22.44.
07/12/19
RAJA
07/12/19
NO CHANGE
RAJA
Outperform
DOJ investigation of J&J 'not new news,' says Raymond James
Raymond James analyst Jayson Bedford said that "technically" it is not "new news" that the DOJ is investigating Johnson & Johnson's communications around the alleged cancer risks of its talcum powder products as J&J previously disclosed an inquiry in its latest 10-Q filing. He notes J&J has responded to a Bloomberg article on the investigation by stating that there have been no new developments, though this risk was "clearly" underappreciated by investors. Though Bedford still thinks J&J has a strong case, today's reaction is an indication that the talc issue will remain "top-of-mind" and a headline risk, he added. Bedford has an Outperform rating on Johnson & Johnson shares.
07/12/19
FBCO
07/12/19
INITIATION
Target $156
FBCO
Outperform
Johnson & Johnson assumed with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic assumed coverage of Johnson & Johnson with an Outperform rating and $156 price target. In a research note to investors, Miksic cites key drivers to the rating, including continued growth in Immunology, driven by Stelera and Tremfya, sustainable growth in Oncology driven by Imbruvica, Darzelex and Erleada, an "attractive" pipeline of filings in the 2019-2023 timeframe with greater than$1B potential each, and "stable" growth and cash flows in Medical Devices and Consumer.
AZN AstraZeneca
$40.20

-0.005 (-0.01%)

05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
GSK GlaxoSmithKline
$41.19

0.29 (0.71%)

05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
06/17/19
MSCO
06/17/19
INITIATION
MSCO
Underweight
GlaxoSmithKline resumed with an Underweight at Morgan Stanley
Morgan Stanley analyst Mark Purcell resumed coverage of GlaxoSmithKline (GSK) with an Underweight rating and 1,520p price target, citing his view that the company's pipeline rebuilding is "very much a work-in-progress." While the Novartis (NVS) was successful in releasing trapped value with the spinout of Alcon (ALC), Purcell sees only "modest" upside from current levels for Glaxo via the value creation from the planned consumer healthcare spinout, he stated.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
RHHBY Roche
$0.00

(0.00%)

06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
06/20/19
LIBR
06/20/19
DOWNGRADE
LIBR
Hold
Roche downgraded to Hold from Buy at Liberum
Liberum analyst Graham Doyle downgraded Roche to Hold from Buy with a price target of 275 francs. The analyst says the shares are "no longer in bargain territory" and that there are a lack of catalysts to move them higher.
MRK Merck
$81.57

0.62 (0.77%)

07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
07/02/19
MZHO
07/02/19
INITIATION
Target $97
MZHO
Buy
Merck initiated with a Buy at Mizuho
Mizuho started Merck with a Buy rating and $97 price target.
LLY Eli Lilly
$108.81

0.36 (0.33%)

06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
SNY Sanofi
$41.82

0.18 (0.43%)

06/20/19
NOMU
06/20/19
NO CHANGE
Target $37
NOMU
Buy
Voyager Therapeutics price target raised to $37 from $26 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Voyager Therapeutics (VYGR) to $37 from $26 after the company announced a restructured deal with Sanofi (SNY). Voyager now has worldwide rights to VY-HTT01 for Huntington's disease, and the ex-U.S. rights to VYFXN01 for Friedreich's ataxia have now been transferred to Neurocrine (NBIX), Marai tells investors in a research note. He believes obtaining the full rights to HTT01 is a positive for Voyager, especially after Roche (RHHBY) "posted positive derisking data." Marai reiterates a Buy rating on Voyager Therapeutics.
06/21/19
STFL
06/21/19
DOWNGRADE
Target $74
STFL
Hold
AnaptysBio downgraded to Hold from Buy at Stifel
Stifel analyst Derek Archila downgraded AnaptysBio (ANAB) to Hold from Buy as he is less confident etokimab will be meaningfully differentiated from Sanofi (SNY) and Regeneron's (REGN) Dupixent after the latter companies reported results from their Phase 2 study for REGN3500, an antiIL-33 antibody, in asthma. REGN3500 did numerically worse than Dupixent as a monotherapy and the combination of REGN3500/Dupixent did not confer a benefit over Dupixent alone, noted Archila. He lowered his view on the odds of success for etokimab to 50% from 55% and also cut his market share assumptions following the competitors' data. Archila cut his price target on AnaptysBio shares to $74 from $124.
07/12/19
MSCO
07/12/19
NO CHANGE
Target $28
MSCO
Equal Weight
Voyager Therapeutics price target raised to $28 from $21 at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung raised his price target on Voyager Therapeutics (VYGR) shares to $28 from $21 after the company recently announced that it will be getting back rights to VY-HTT01 for Huntington's disease in a restructuring of its partnership with Sanofi Genzyme (SNY). While early in development, Hungs think VY-HTT01 could be a roughly $900M product for Voyager. Although he appreciates the opportunity in Huntington's and is "constructive" on VY-AADC in Parkinson's, Hung keeps an Equal Weight rating on Voyager shares, citing what he sees as limited near-term clinical catalysts.
PFE Pfizer
$42.85

0.1 (0.23%)

07/08/19
PIPR
07/08/19
NO CHANGE
PIPR
Overweight
BioMarin's Valrox maintains competitive advantage, says Piper Jaffray
After BioMarin (BMRN) announced that the company will submit regulatory filings for Valrox to both the FDA and EMA in Q4, and after the company and competitive partners Sangamo (SGMO) and Pfizer (PFE) both presented updates at this weekend's International Society on Thrombosis and Hemostasis meeting, Piper Jaffray analyst Christopher Raymond said that he still believes the company's roughly 2-year head start puts Valrox at a competitive advantage. Following the confirmation on timing for accelerated filing, Raymond said he would continue to be a buyer of BioMarin shares and he keeps an Overweight rating on the stock.
07/17/19
ADAM
07/17/19
NO CHANGE
Target $125
ADAM
Buy
Exact Sciences price target raised to $125 from $118 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) to $125 from $118 following meetings with management. The analyst said the meetings were upbeat as current momentum appears solid and poised to continue for the foreseeable future. Management conveyed the Pfizer (PFE) partnership has been a "home run" and Massaro expects the momentum to accelerate. Massaro reiterated his Buy rating on Exact Sciences shares.
07/09/19
MSCO
07/09/19
NO CHANGE
Target $220
MSCO
Overweight
Sarepta price target raised to $220 from $165 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target for Sarepta Therapeutics (SRPT) to $220 from $165 while keeping an Overweight rating on the shares. The stock closed Monday down $4.52 to $146.28. The company's Duchenne muscular dystrophy gene therapy is positioned to be the first to market, taking a majority share of the ~$20B prevalent population in the U.S. and expanding internationally with a "significant" lead, Harrison tells investors in a research note. He believes Sarepta has higher efficacy than top-line Pfizer (PFE) data suggest. Sarepta's dystrophin expression is likely three-times greater, fiber intensity 15%, and positive fibers 12.5%, contends the analyst. Harrison believes Sarepta has a "broad therapeutic window" and should now take majority market share.

TODAY'S FREE FLY STORIES

FB

Facebook

$183.45

-6.37 (-3.36%)

, GOOG

Alphabet

$1,246.51

0.28 (0.02%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Periodicals
U.S antitrust chief says breakup of 'Big Tech' is 'on the table,' WSJ reports »

Makan Delrahim, the U.S.…

FB

Facebook

$183.45

-6.37 (-3.36%)

GOOG

Alphabet

$1,246.51

0.28 (0.02%)

AMZN

Amazon.com

$1,769.36

-15.37 (-0.86%)

AAPL

Apple

$242.10

1.61 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 21

    Nov

GME

GameStop

$6.30

0.37 (6.24%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

, SPX

S&P 500

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
General news
Brexit withdrawal agreement bill passes by 329-299 vote, Bloomberg reports »

The U.K. Parliament is…

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/22/19
10/22
14:16
10/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
10/22/19
10/22
14:10
10/22/19
14:10
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

UTX

United Technologies

$141.32

3.08 (2.23%)

, BA

Boeing

$339.38

8.26 (2.49%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Periodicals
United Tech sees no extra cut in Boeing 737 MAX production in 2019, Reuters says »

United Technologies (UTX)…

UTX

United Technologies

$141.32

3.08 (2.23%)

BA

Boeing

$339.38

8.26 (2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

LLY

Eli Lilly

$109.84

1.9 (1.76%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Earnings
Fly Intel: What to watch in Eli Lilly earnings report »

Eli Lilly (LLY) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

FCX

Freeport McMoRan

$9.95

0.13 (1.32%)

14:05
10/22/19
10/22
14:05
10/22/19
14:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WBS

Webster Financial

$44.80

-2.51 (-5.31%)

14:01
10/22/19
10/22
14:01
10/22/19
14:01
Downgrade
Webster Financial rating change  »

Compass Point cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

WBS

Webster Financial

$44.69

-2.62 (-5.54%)

13:58
10/22/19
10/22
13:58
10/22/19
13:58
Downgrade
Webster Financial rating change  »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

13:55
10/22/19
10/22
13:55
10/22/19
13:55
Conference/Events
House Financial Services Committee to hold a hearing »

The Subcommittee on…

SYMC

Symantec

$23.19

0.11 (0.48%)

13:55
10/22/19
10/22
13:55
10/22/19
13:55
Conference/Events
House Committee on Homeland Security to hold a hearing »

The Cybersecurity,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LYFT

Lyft

$44.73

3.87 (9.47%)

, UBER

Uber

$33.79

2.375 (7.56%)

13:47
10/22/19
10/22
13:47
10/22/19
13:47
Recommendations
Lyft, Uber analyst commentary  »

Lyft profit call…

LYFT

Lyft

$44.73

3.87 (9.47%)

UBER

Uber

$33.79

2.375 (7.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

FEYE

FireEye

$15.67

0.255 (1.65%)

13:45
10/22/19
10/22
13:45
10/22/19
13:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 09

    Dec

  • 12

    Dec

13:45
10/22/19
10/22
13:45
10/22/19
13:45
General news
Treasury Action: the 2-year yield dropped on the good auction results »

Treasury Action: the…

MCD

McDonald's

$201.55

-8.295 (-3.95%)

13:45
10/22/19
10/22
13:45
10/22/19
13:45
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PRGS

Progress Software

$39.56

-0.06 (-0.15%)

13:44
10/22/19
10/22
13:44
10/22/19
13:44
Initiation
Progress Software initiated  »

Progress Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BIIB

Biogen

$291.60

68.03 (30.43%)

13:39
10/22/19
10/22
13:39
10/22/19
13:39
Recommendations
Biogen analyst commentary  »

Biogen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JBHT

J.B. Hunt

$116.80

1.42 (1.23%)

, KNX

Knight-Swift

$37.00

0.17 (0.46%)

13:38
10/22/19
10/22
13:38
10/22/19
13:38
Hot Stocks
ATA says truck tonnage index rose 0.2% in September »

American Trucking…

JBHT

J.B. Hunt

$116.80

1.42 (1.23%)

KNX

Knight-Swift

$37.00

0.17 (0.46%)

ODFL

Old Dominion

$179.81

-0.14 (-0.08%)

SWFT

Swift Transportation

$0.00

(0.00%)

WERN

Werner

$37.39

0.47 (1.27%)

ARCB

ArcBest

$29.91

-0.62 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 01

    Nov

  • 13

    Nov

BA

Boeing

$338.95

7.83 (2.36%)

, TMO

Thermo Fisher

$283.75

0.3 (0.11%)

13:36
10/22/19
10/22
13:36
10/22/19
13:36
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$338.95

7.83 (2.36%)

TMO

Thermo Fisher

$283.75

0.3 (0.11%)

LLY

Eli Lilly

$109.81

1.87 (1.73%)

CAT

Caterpillar

$132.73

0.51 (0.39%)

ANTM

Anthem

$263.46

10.3 (4.07%)

BX

Blackstone

$49.33

0.225 (0.46%)

BSX

Boston Scientific

$38.79

0.13 (0.34%)

GD

General Dynamics

$179.02

3.59 (2.05%)

NSC

Norfolk Southern

$187.37

1.2 (0.64%)

HLT

Hilton

$92.41

0.03 (0.03%)

FCX

Freeport McMoRan

$9.96

0.14 (1.43%)

IVZ

Invesco

$16.13

-0.015 (-0.09%)

OC

Owens Corning

$63.55

0.085 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

SGMS

Scientific Games

$23.49

0.745 (3.28%)

, IGT

International Game

$14.11

0.34 (2.47%)

13:34
10/22/19
10/22
13:34
10/22/19
13:34
Recommendations
Scientific Games, International Game analyst commentary  »

Brazil win potentially…

SGMS

Scientific Games

$23.49

0.745 (3.28%)

IGT

International Game

$14.11

0.34 (2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$95.93

0.84 (0.88%)

13:33
10/22/19
10/22
13:33
10/22/19
13:33
Upgrade
Xilinx rating change  »

Xilinx upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 20

    Nov

TXN

Texas Instruments

$129.82

-1.11 (-0.85%)

, DFS

Discover

$81.61

1.16 (1.44%)

13:33
10/22/19
10/22
13:33
10/22/19
13:33
Earnings
Notable companies reporting after market close »

Notable companies…

TXN

Texas Instruments

$129.82

-1.11 (-0.85%)

DFS

Discover

$81.61

1.16 (1.44%)

CMG

Chipotle

$832.60

-19.28 (-2.26%)

SNAP

Snap

$14.10

-0.48 (-3.29%)

TER

Teradyne

$59.18

-0.89 (-1.48%)

WHR

Whirlpool

$161.17

0.63 (0.39%)

SKX

Skechers

$37.97

0.49 (1.31%)

SIX

Six Flags

$51.41

-0.43 (-0.83%)

NAVI

Navient

$12.09

0.12 (1.00%)

IRBT

iRobot

$55.39

-0.31 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 21

    Nov

  • 09

    Dec

DIS

Disney

$133.40

3.12 (2.39%)

13:26
10/22/19
10/22
13:26
10/22/19
13:26
Hot Stocks
Disney CEO says American consumer outlook 'still relatively positive' »

Bob Iger is speaking on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.